NCT01664728View on ClinicalTrials.gov

An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

September 30, 2012

Conditions
Prostate Neoplasms
Interventions
DRUG

Abiraterone acetate

Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily

DRUG

Glucocorticoid

prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily

Trial Locations (1)

Unknown

Sutton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01664728 - An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 | Biotech Hunter | Biotech Hunter